Conventional T cell immune therapy, including antibodies against PD-L1 and PD-1, are currently used for advanced bladder cancer, and are thought to depend on tumor-antigen presentation by an intact MHC I receptor. The gene discussed is CD274; the disease is urinary bladder carcinoma.